The two main Tekturna outcomes studies are in HF and type-2 diabetes—i.e. neither is a vanilla hypertension study.
That's right but Tekturna is a first with the class of renin inhibitors, which are the first new class of antihypertensives to be launched in over a decade, therefore, I think docs are likely to wait for more data (including outcomes data).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.